KR20160016973A - P38 - map 키나아제 억제제로서 [1, 2, 4] 트리아졸로 [4, 3 - a] 피리딘의 유도체 - Google Patents

P38 - map 키나아제 억제제로서 [1, 2, 4] 트리아졸로 [4, 3 - a] 피리딘의 유도체 Download PDF

Info

Publication number
KR20160016973A
KR20160016973A KR1020157037285A KR20157037285A KR20160016973A KR 20160016973 A KR20160016973 A KR 20160016973A KR 1020157037285 A KR1020157037285 A KR 1020157037285A KR 20157037285 A KR20157037285 A KR 20157037285A KR 20160016973 A KR20160016973 A KR 20160016973A
Authority
KR
South Korea
Prior art keywords
pyridin
triazolo
yloxy
tetrahydro
naphthalen
Prior art date
Application number
KR1020157037285A
Other languages
English (en)
Korean (ko)
Inventor
릴리안 알카라즈
테리 애론 판칼
앤드류 스테판 로버트 제닝스
앤드류 피터 크리드랜드
크리스토퍼 헐리
Original Assignee
키에시 파르마슈티시 엣스. 피. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 키에시 파르마슈티시 엣스. 피. 에이. filed Critical 키에시 파르마슈티시 엣스. 피. 에이.
Publication of KR20160016973A publication Critical patent/KR20160016973A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020157037285A 2013-06-06 2013-06-06 P38 - map 키나아제 억제제로서 [1, 2, 4] 트리아졸로 [4, 3 - a] 피리딘의 유도체 KR20160016973A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/061706 WO2014194956A1 (en) 2013-06-06 2013-06-06 Derivatives of [1, 2, 4] triazolo [4, 3 - a] pyridine as p38 - map kinase inhibitors

Publications (1)

Publication Number Publication Date
KR20160016973A true KR20160016973A (ko) 2016-02-15

Family

ID=48628635

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157037285A KR20160016973A (ko) 2013-06-06 2013-06-06 P38 - map 키나아제 억제제로서 [1, 2, 4] 트리아졸로 [4, 3 - a] 피리딘의 유도체

Country Status (9)

Country Link
US (1) US9573949B2 (zh)
EP (1) EP3004087B1 (zh)
KR (1) KR20160016973A (zh)
CN (1) CN105308044A (zh)
BR (1) BR112015029504A2 (zh)
CA (1) CA2914457A1 (zh)
HK (1) HK1219101A1 (zh)
RU (1) RU2637944C2 (zh)
WO (1) WO2014194956A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101994381B1 (ko) 2011-12-09 2019-06-28 키에시 파르마슈티시 엣스. 피. 에이. 키나아제 억제제
MA44131A (fr) * 2015-12-23 2021-05-26 Chiesi Farm Spa Dérivés de 1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urée et leur utlisation en tant qu'inhibiteurs de p38 mapk
WO2017108737A1 (en) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
AU2017281222B2 (en) * 2016-06-23 2022-06-16 The Usa As Represented By The Department Of Veterans Affairs; Dept. Of Veterans Affairs Office Of General Counsel - Pag Iv (024) Non-catalytic substrate-selective P38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
CN108424372B (zh) * 2018-05-11 2021-08-10 浙江华贝药业有限责任公司 2，2，2-三氟-n-[(s)-4-羰基四氢萘-1-基]-乙酰胺的纯化工艺
CN115650824B (zh) * 2022-10-31 2024-01-23 合肥工业大学 手性二醇及其制备方法、制得的催化剂及制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
CA2445003A1 (en) * 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents
DK1778686T3 (da) * 2004-08-12 2009-01-12 Pfizer Triazolopyridinylsulfanylderivater som P38 MAP kinase-inhibitorer
US20090012079A1 (en) * 2006-02-09 2009-01-08 Russell Andrew Lewthwaite Triazolopyridine Compounds
WO2010094956A1 (en) * 2009-02-17 2010-08-26 Pulmagen Therapeutics (Inflammation) Limited. Triazolopyridine derivatives as p38 map kinase inhibitors
GB201009731D0 (en) * 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
KR101994381B1 (ko) 2011-12-09 2019-06-28 키에시 파르마슈티시 엣스. 피. 에이. 키나아제 억제제
BR112015029970A2 (pt) * 2013-06-06 2017-07-25 Chiesi Farm Spa inibidores de cinase

Also Published As

Publication number Publication date
CN105308044A (zh) 2016-02-03
RU2015151823A (ru) 2017-06-13
BR112015029504A2 (pt) 2017-07-25
HK1219101A1 (zh) 2017-03-24
US20160108040A1 (en) 2016-04-21
EP3004087A1 (en) 2016-04-13
CA2914457A1 (en) 2014-12-11
WO2014194956A1 (en) 2014-12-11
US9573949B2 (en) 2017-02-21
RU2637944C2 (ru) 2017-12-08
EP3004087B1 (en) 2017-08-09

Similar Documents

Publication Publication Date Title
KR101994381B1 (ko) 키나아제 억제제
EP3004087B1 (en) Derivatives of [1,2,4]triazolo[4,3-a]pyridine as p38-map kinase inhibitors
US9181242B2 (en) Kinase inhibitors
JP5511805B2 (ja) ｐ３８キナーゼ阻害剤としてのピロロ［２，３−ｃ］ピリジン誘導体
EP2580212B1 (en) Urea derivatives and their therapeutic use in the treatment of, inter alia, diseases of the respiratory tract
EP3004098B1 (en) Kinase inhibitors
EP2788345B1 (en) Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
JP6145849B2 (ja) キナーゼ阻害剤
EP2398777B1 (en) Pyrimidopyridazine derivatives useful as p38 mapk inhibitors
EP3394058B1 (en) N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
US9758521B2 (en) Kinase inhibitors
US10364245B2 (en) Kinase inhibitors

Legal Events

Date Code Title Description
WITN Withdrawal due to no request for examination